Gout, a painful form of arthritis caused by elevated uric acid levels, is on the rise. According to projections, the number of cases globally is expected to rise significantly over the next 25 years. In the United States alone, over 9 million people have been diagnosed with gout, and an alarming 44 million people have uric acid levels above the normal range, putting them at risk. This surge is attributed to an aging population, obesity, and lifestyle choices, leading to severe pain, reduced quality of life, and increased healthcare costs.
Current treatments, primarily oral xanthine oxidase inhibitors (XOIs), are effective for many but come with significant drawbacks. Approximately 3% to 5% of patients cannot tolerate them, and they carry boxed warnings for cardiovascular risk. Other side effects include severe gastrointestinal issues, kidney toxicity, and paradoxical flare-ups, which hinder patient adherence. These limitations underscore the urgent need for better options.
XORTX Therapeutics Inc. (NASDAQ: XRTX), a late-stage clinical pharmaceutical company, is developing XORLO™, a proprietary formulation of oxypurinol designed to overcome these challenges. XORLO utilizes a liposomal delivery system to enhance oral absorption, allowing for lower total daily doses and reduced side effects. The company recently announcing the launch of drug material and tablet manufacturing to support a planned two-part clinical study, XRX-OXY-102. This study, based on positive prior results and FDA discussions, aims to characterize the pharmacokinetics and efficacy of XORLO.
XORTX is also working toward a new drug application submission to the FDA. The company has prepared a new Investigational New Drug (IND) application for submission in the fourth quarter of 2026 and intends to file a New Drug Application (NDA) once the clinical trial is complete. XORTX is targeting an NDA submission in about one year and estimates a market opportunity of $700 million annually for XORLO. "Our planned IND submission to the FDA next quarter is a defining step for the XRx-026 program," said Allen Davidoff, Co-CEO of XORTX. "It reflects the strength of our prior clinical results and moves us closer to potentially offering gout patients a differentiated treatment option."
The implications of XORTX's progress are significant. With gout prevalence projected to climb, a better-tolerated and more effective treatment could improve patient outcomes and reduce healthcare burdens. XORLO's potential to lower uric acid at lower doses may address adherence issues that plague current therapies. As XORTX advances toward an NDA, it positions itself to capture a substantial share of the growing gout market. For more details, see the published on Benzinga and the original release on www.newmediawire.com.
